Endothelial thrombomodulin downregulation caused by hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient lungs.


Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 18 08 2021
revised: 28 11 2021
accepted: 30 12 2021
pubmed: 17 1 2022
medline: 2 2 2022
entrez: 16 1 2022
Statut: ppublish

Résumé

Thromboembolism is a life-threatening manifestation of coronavirus disease 2019 (COVID-19). We investigated a dysfunctional phenotype of vascular endothelial cells in the lungs during COVID-19. We obtained the lung specimens from the patients who died of COVID-19. The phenotype of endothelial cells and immune cells was examined by flow cytometry and immunohistochemistry (IHC) analysis. We tested the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the endothelium using IHC and electron microscopy. The autopsy lungs of COVID-19 patients exhibited severe coagulation abnormalities, immune cell infiltration, and platelet activation. Pulmonary endothelial cells of COVID-19 patients showed increased expression of procoagulant von Willebrand factor (VWF) and decreased expression of anticoagulants thrombomodulin and endothelial protein C receptor (EPCR). In the autopsy lungs of COVID-19 patients, the number of macrophages, monocytes, and T cells was increased, showing an activated phenotype. Despite increased immune cells, adhesion molecules such as ICAM-1, VCAM-1, E-selectin, and P-selectin were downregulated in pulmonary endothelial cells of COVID-19 patients. Notably, decreased thrombomodulin expression in endothelial cells was associated with increased immune cell infiltration in the COVID-19 patient lungs. There were no SARS-CoV-2 particles detected in the lung endothelium of COVID-19 patients despite their dysfunctional phenotype. Meanwhile, the autopsy lungs of COVID-19 patients showed SARS-CoV-2 virions in damaged alveolar epithelium and evidence of hypoxic injury. Pulmonary endothelial cells become dysfunctional during COVID-19, showing a loss of thrombomodulin expression related to severe thrombosis and infiltration, and endothelial cell dysfunction might be caused by a pathologic condition in COVID-19 patient lungs rather than a direct infection with SARS-CoV-2. This work was supported by the Johns Hopkins University, the American Heart Association, and the National Institutes of Health.

Sections du résumé

BACKGROUND BACKGROUND
Thromboembolism is a life-threatening manifestation of coronavirus disease 2019 (COVID-19). We investigated a dysfunctional phenotype of vascular endothelial cells in the lungs during COVID-19.
METHODS METHODS
We obtained the lung specimens from the patients who died of COVID-19. The phenotype of endothelial cells and immune cells was examined by flow cytometry and immunohistochemistry (IHC) analysis. We tested the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the endothelium using IHC and electron microscopy.
FINDINGS RESULTS
The autopsy lungs of COVID-19 patients exhibited severe coagulation abnormalities, immune cell infiltration, and platelet activation. Pulmonary endothelial cells of COVID-19 patients showed increased expression of procoagulant von Willebrand factor (VWF) and decreased expression of anticoagulants thrombomodulin and endothelial protein C receptor (EPCR). In the autopsy lungs of COVID-19 patients, the number of macrophages, monocytes, and T cells was increased, showing an activated phenotype. Despite increased immune cells, adhesion molecules such as ICAM-1, VCAM-1, E-selectin, and P-selectin were downregulated in pulmonary endothelial cells of COVID-19 patients. Notably, decreased thrombomodulin expression in endothelial cells was associated with increased immune cell infiltration in the COVID-19 patient lungs. There were no SARS-CoV-2 particles detected in the lung endothelium of COVID-19 patients despite their dysfunctional phenotype. Meanwhile, the autopsy lungs of COVID-19 patients showed SARS-CoV-2 virions in damaged alveolar epithelium and evidence of hypoxic injury.
INTERPRETATION CONCLUSIONS
Pulmonary endothelial cells become dysfunctional during COVID-19, showing a loss of thrombomodulin expression related to severe thrombosis and infiltration, and endothelial cell dysfunction might be caused by a pathologic condition in COVID-19 patient lungs rather than a direct infection with SARS-CoV-2.
FUNDING BACKGROUND
This work was supported by the Johns Hopkins University, the American Heart Association, and the National Institutes of Health.

Identifiants

pubmed: 35033854
pii: S2352-3964(22)00001-9
doi: 10.1016/j.ebiom.2022.103812
pmc: PMC8756077
pii:
doi:

Substances chimiques

THBD protein, human 0
Thrombomodulin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103812

Subventions

Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK093770
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL136586
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118183
Pays : United States
Organisme : NHLBI NIH HHS
ID : F31 HL149328
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM110674
Pays : United States
Organisme : NIAMS NIH HHS
ID : F31 AR077406
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL147660
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI143773
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400007C
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007417
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL138497
Pays : United States

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of interests None exist.

Auteurs

Taejoon Won (T)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Megan K Wood (MK)

W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA.

David M Hughes (DM)

Department of Chemical and Biomolecular Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, MD 21218, USA.

Monica V Talor (MV)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Zexu Ma (Z)

W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA.

Jowaly Schneider (J)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

John T Skinner (JT)

Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Beejan Asady (B)

W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA.

Erin Goerlich (E)

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Marc K Halushka (MK)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Allison G Hays (AG)

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Deok-Ho Kim (DH)

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Biomedical Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, MD 21218, USA.

Chirag R Parikh (CR)

Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Avi Z Rosenberg (AZ)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Isabelle Coppens (I)

W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA.

Roger A Johns (RA)

Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Nisha A Gilotra (NA)

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Jody E Hooper (JE)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Andrew Pekosz (A)

W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA.

Daniela Čiháková (D)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA. Electronic address: cihakova@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH